Skip to main content
SpringerLink
Log in

Pulmonary Complications of Lung Cancer Treatment

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Respiratory Medicine ((RM))

  • 346 Accesses

Abstract

Advances in lung cancer therapies have yielded substantial improvements in disease response and survival. As treatment paradigms have evolved, so has our understanding of the attendant complications accompanying these life-saving therapies. Since most treatment-related pulmonary complications present with nonspecific respiratory symptoms and radiographic findings, an accurate diagnosis requires understanding of patient- and treatment-related risk factors and a systematic approach to evaluation. These events present diagnostic challenges for clinicians with meaningful consequences for patients. In this chapter, we will address pulmonary complications arising from radiation therapy, traditional chemotherapy, immunotherapy, and molecularly targeted agents, highlighting common themes in evaluation and management and acknowledging areas of uncertainty.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004;25(1):53–64.

    Article  PubMed  Google Scholar 

  2. Muller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91(Suppl 2):S24–30.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gaga M, Powell CA, Schraufnagel DE, Schonfeld N, Rabe K, Hill NS, et al. An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med. 2013;188(4):503–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bahig H, Filion E, Vu T, Chalaoui J, Lambert L, Roberge D, et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol. 2016;6(5):367–74.

    Article  PubMed  Google Scholar 

  5. Monson JM, Stark P, Reilly JJ, Sugarbaker DJ, Strauss GM, Swanson SJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 1998;82(5):842–50.

    Article  CAS  PubMed  Google Scholar 

  6. Abratt RP, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med. 2004;25(1):167–77.

    Article  PubMed  Google Scholar 

  7. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):457–62.

    Article  PubMed  Google Scholar 

  8. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(4):1017–23.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bledsoe TJ, Nath SK, Decker RH. Radiation pneumonitis. Clin Chest Med. 2017;38(2):201–8.

    Article  PubMed  Google Scholar 

  10. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2000;48(1):89–94.

    Article  CAS  PubMed  Google Scholar 

  11. Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82(2):260–5.

    Article  PubMed  Google Scholar 

  12. Forschner A, Zips D, Schraml C, Rocken M, Iordanou E, Leiter U, et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res. 2014;24(5):512–6.

    Article  PubMed  Google Scholar 

  13. Cousin F, Desir C, Ben Mustapha S, Mievis C, Coucke P, Hustinx R. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer. Radiother Oncol. 2021;157:47–55.

    Article  CAS  PubMed  Google Scholar 

  14. Adhikari B, Dongol RM, Baral D, Hewett Y, Shah BK. Pemetrexed and interstitial lung disease. Acta Oncol. 2016;55(4):521–2.

    Article  CAS  PubMed  Google Scholar 

  15. Harada H, Seto T, Igawa S, Tsuya A, Wada M, Kaira K, et al. Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). Int J Radiat Oncol Biol Phys. 2012;82(5):1777–82.

    Article  CAS  PubMed  Google Scholar 

  16. Jia W, Gao Q, Wang M, Li J, Jing W, Yu J, et al. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Radiat Oncol. 2021;16(1):41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys. 1995;31(5):1187–203.

    Article  CAS  PubMed  Google Scholar 

  18. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest. 2019;156(1):150–62.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Common Terminology Criteria for Adverse Events (CTCAE). 2017. Accessed 29 Aug 2022.

    Google Scholar 

  20. Zhang P, Yan H, Wang S, Kai J, Pi G, Peng Y, et al. Post-radiotherapy maintenance treatment with fluticasone propionate and salmeterol for lung cancer patients with grade III radiation pneumonitis: a case report. Medicine (Baltimore). 2018;97(21):e10681.

    Article  CAS  PubMed  Google Scholar 

  21. Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004;25(1):37–45.

    Article  PubMed  Google Scholar 

  22. Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer. 2004;91(Suppl 2):S1–2.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301–26.

    Article  PubMed  Google Scholar 

  24. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004;91(Suppl 2):S18–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. NCCN. Management of immunotherapy-related toxicities. National Comprehensive Cancer Network. v1.2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.

  26. Hanna NH, Schneider BJ, Temin S, Baker S Jr, Brahmer J, Ellis PM, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2020;38(14):1608–32.

    Article  PubMed  Google Scholar 

  27. NCCN. Non-small cell lung cancer. National Comprehensive Cancer Network. v3.2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

  28. NCCN. Small cell lung cancer. National Comprehensive Cancer Network. v2.2022. 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.

  29. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee YG, Lee E, Kim I, Lee KW, Kim TM, Lee SH, et al. Cisplatin-based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer. Cancer Res Treat. 2015;47(4):670–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001;85(9):1247–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Graziano SL, Herndon JE II, Socinski MA, Wang X, Watson D, Vokes E, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008;3(2):158–62.

    Article  PubMed  Google Scholar 

  33. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012;32(3):1103–6.

    PubMed  Google Scholar 

  34. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006;129(4):1031–8.

    Article  CAS  PubMed  Google Scholar 

  35. Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 2000;36(18):2329–34.

    Article  CAS  PubMed  Google Scholar 

  36. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer. 2003;40(1):79–84.

    Article  PubMed  Google Scholar 

  37. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;16(10):3426–32.

    Article  CAS  PubMed  Google Scholar 

  38. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 2008;14(13):4206–12.

    Article  CAS  PubMed  Google Scholar 

  39. Tomii K, Kato T, Takahashi M, Noma S, Kobashi Y, Enatsu S, et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol. 2017;47(4):350–6.

    Article  PubMed  Google Scholar 

  40. Eagle Pharmaceuticals. Pemfexy (pemetrexed) package insert. Woodcliff Lake, NJ: Eagle Pharmaceuticals; 2020.

    Google Scholar 

  41. Hochstrasser A, Benz G, Joerger M, Templeton A, Brutsche M, Fruh M. Interstitial pneumonitis after treatment with pemetrexed: a rare event? Chemotherapy. 2012;58(1):84–8.

    Article  CAS  PubMed  Google Scholar 

  42. Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18(1):85–91.

    Article  CAS  PubMed  Google Scholar 

  43. Arrieta O, Gallardo-Rincon D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Martinez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol. 2009;4(7):845–52.

    Article  PubMed  Google Scholar 

  44. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80(2):286–91.

    Article  CAS  PubMed  Google Scholar 

  45. Binder D, Hubner RH, Temmesfeld-Wollbruck B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials. Cancer Chemother Pharmacol. 2011;68(6):1575–83.

    Article  CAS  PubMed  Google Scholar 

  46. Dajczman E, Srolovitz H, Kreisman H, Frank H. Fatal pulmonary toxicity following oral etoposide therapy. Lung Cancer. 1995;12(1–2):81–6.

    Article  CAS  PubMed  Google Scholar 

  47. Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide-induced pulmonary toxicity. Lung Cancer. 1999;26(2):109–12.

    Article  CAS  PubMed  Google Scholar 

  48. Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer. 2006;54(2):243–5.

    Article  PubMed  Google Scholar 

  49. Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S, et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol. 2013;43(5):483–91.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Pfizer Injectables. Irinotecan package insert. New York, NY: Pfizer Injectables; 2014.

    Google Scholar 

  51. Teva Pharmaceuticals. Topotecan injection package insert. North Wales, PA: Teva Pharmaceuticals; 2014.

    Google Scholar 

  52. Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anti-Cancer Drugs. 2011;22(6):563–8.

    Article  CAS  PubMed  Google Scholar 

  53. Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anti-Cancer Drugs. 2000;11(9):709–13.

    Article  CAS  PubMed  Google Scholar 

  54. Tanvetyanon T, Garrity ER, Albain KS. Acute lung injury associated with vinorelbine. J Clin Oncol. 2006;24(12):1952–3.

    Article  PubMed  Google Scholar 

  55. Ribeiro de Oliveira Santos MB, Mergulhao P. Vinorelbine-induced acute respiratory distress syndrome treated with non-invasive ventilation and immunosuppressive therapy. Respirol Case Rep. 2018;6(7):e00349.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Singh S, Jaigirdar AA, Mulkey F, Cheng J, Hamed SS, Li Y, et al. FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer. Clin Cancer Res. 2021;27(9):2378–82.

    Article  CAS  PubMed  Google Scholar 

  57. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neuro-Oncol. 2001;53(3):259–65.

    Article  CAS  Google Scholar 

  58. Maldonado F, Limper AH, Lim KG, Aubrey MC. Temozolomide-associated organizing pneumonitis. Mayo Clin Proc. 2007;82(6):771–3.

    Article  PubMed  Google Scholar 

  59. Koschel D, Handzhiev S, Leucht V, Holotiuk O, Fisseler-Eckhoff A, Hoffken G. Hypersensitivity pneumonitis associated with the use of temozolomide. Eur Respir J. 2009;33(4):931–4.

    Article  CAS  PubMed  Google Scholar 

  60. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol. 2013;85(3):373–82.

    Article  PubMed  Google Scholar 

  61. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015;26(9):1824–9.

    Article  CAS  PubMed  Google Scholar 

  63. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.

    Article  CAS  PubMed  Google Scholar 

  64. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv42.

    Article  CAS  PubMed  Google Scholar 

  65. Reuss JE, Suresh K, Naidoo J. Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond. Curr Oncol Rep. 2020;22(6):56.

    Article  PubMed  Google Scholar 

  66. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–16.

    Article  PubMed  Google Scholar 

  67. Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13(12):1930–9.

    Article  CAS  PubMed  Google Scholar 

  68. Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis. Chest. 2022;161(6):1675–86.

    Article  CAS  PubMed  Google Scholar 

  69. Cadranel J, Canellas A, Matton L, Darrason M, Parrot A, Naccache JM, et al. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev. 2019;28(153):190058.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021;32(9):1137–47.

    Article  CAS  PubMed  Google Scholar 

  72. Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507–16.

    Article  CAS  PubMed  Google Scholar 

  73. Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112–5.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.

    Article  CAS  PubMed  Google Scholar 

  76. Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 2021;7:1.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.

    Article  CAS  PubMed  Google Scholar 

  78. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48.

    Article  CAS  PubMed  Google Scholar 

  79. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53.

    Article  PubMed  Google Scholar 

  80. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–126.

    Article  CAS  PubMed  Google Scholar 

  81. Balaji A, Hsu M, Lin CT, Feliciano J, Marrone K, Brahmer JR, et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 2021;9(1):e001731.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Cabanie C, Ammari S, Hans S, Pobel C, Laparra A, Danlos FX, et al. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study. Eur J Cancer. 2021;156:46–59.

    Article  CAS  PubMed  Google Scholar 

  85. Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS. Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event. Cancer Immunol Res. 2018;6(6):630–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, et al. Bevacizumab for non-small-cell lung cancer: a nested case control study of risk factors for hemoptysis. Cancer Sci. 2016;107(12):1837–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–91.

    Article  CAS  PubMed  Google Scholar 

  88. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–40.

    Article  CAS  PubMed  Google Scholar 

  89. Genetech. Avastin (bevacizumab) package insert. South San Francisco, CA: Genetech; 2017.

    Google Scholar 

  90. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28(1):43–8.

    Article  CAS  PubMed  Google Scholar 

  91. Eli Lilly and Company. Cyramza (ramucirumab) package insert. Indianapolis, IN: Eli Lilly and Company; 2020.

    Google Scholar 

  92. Xie X, Wang X, Wu S, Yang H, Liu J, Chen H, et al. Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. J Thorac Dis. 2020;12(8):4057–69.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Suh CH, Park HS, Kim KW, Pyo J, Hatabu H, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer. 2018;123:60–9.

    Article  PubMed  Google Scholar 

  94. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8(4):303–6.

    Article  CAS  PubMed  Google Scholar 

  95. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.

    Article  CAS  PubMed  Google Scholar 

  96. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010;5(10):1616–22.

    Article  PubMed  Google Scholar 

  97. Pfizer Labs. Vizimpro (dacomitinib) package insert. New York, NY: Pfizer Labs; 2018.

    Google Scholar 

  98. Takeda Pharmaceuticals America. Exkivity (mobocertinib) package insert. Cambridge, MA: Takeda Pharmaceuticals America; 2021.

    Google Scholar 

  99. Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, et al. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. Thorac Cancer. 2019;10(4):975–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30(5):839–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Jia Y, Zhao S, Jiang T, Li X, Zhao C, Liu Y, et al. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Lung Cancer. 2019;137:85–93.

    Article  PubMed  Google Scholar 

  102. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer. 2006;52(2):135–40.

    Article  PubMed  Google Scholar 

  103. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(6):537–43.

    Article  PubMed  Google Scholar 

  104. Lee H, Lee HY, Sun JM, Lee SH, Kim Y, Park SE, et al. Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol. 2018;13(8):1106–12.

    Article  CAS  PubMed  Google Scholar 

  105. Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, et al. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010;5(11):1855–8.

    Article  PubMed  Google Scholar 

  106. Janssen Biotech. Rybrevant (amivantamab) package insert. Horsham Township, PA: Janssen Biotech; 2021.

    Google Scholar 

  107. Eli Lilly and Company. Portrazza (necitumumab) package insert. Indianapolis, IN: Eli Lilly and Company; 2015.

    Google Scholar 

  108. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(12):1683–96.

    Article  CAS  PubMed  Google Scholar 

  109. Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer. 2018;19(2):e151–e61.

    Article  CAS  PubMed  Google Scholar 

  110. Au TH, Cavalieri CC, Stenehjem DD. Ceritinib: a primer for pharmacists. J Oncol Pharm Pract. 2017;23(8):602–14.

    Article  CAS  PubMed  Google Scholar 

  111. Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, et al. Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib. J Thorac Oncol. 2019;14(4):672–82.

    Article  CAS  PubMed  Google Scholar 

  112. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Dev Ther. 2011;5:471–85.

    Article  Google Scholar 

  113. Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, et al. Interstitial lung disease associated with crizotinib in patients with advanced non-small cell lung cancer: independent review of four PROFILE trials. Clin Lung Cancer. 2017;18(5):472–9.

    Article  CAS  PubMed  Google Scholar 

  114. Wu Y, Chen H, Guan J, Zhang K, Wu W, Li X, et al. Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: a case report and literature review. Medicine (Baltimore). 2021;100(26):e26449.

    Article  PubMed  Google Scholar 

  115. Harrison PK, Boland HE, Aherne NJ, Palmieri DJ. An unusual case of lorlatinib-induced pneumonitis: a case report. Case Rep Oncol. 2022;15(1):225–30.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Lin L, Zhao J, Kong N, He Y, Hu J, Huang F, et al. Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. Oncotarget. 2017;8(34):57379–85.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Chalmers A, Cannon L, Akerley W. Adverse event management in patients with BRAF V600E-mutant non-small cell lung cancer treated with dabrafenib plus trametinib. Oncologist. 2019;24(7):963–72.

    Article  PubMed  Google Scholar 

  118. Novartis Pharmaceuticals Corporation. Mekinist (trametinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

    Google Scholar 

  119. Schmitt L, Schumann T, Loser C, Dippel E. Vemurafenib-induced pulmonary injury. Onkologie. 2013;36(11):685–6.

    PubMed  Google Scholar 

  120. Lheure C, Kramkimel N, Franck N, Laurent-Roussel S, Carlotti A, Queant A, et al. Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation. Dermatology. 2015;231(4):378–84.

    Article  CAS  PubMed  Google Scholar 

  121. Camus P. The drug-induced respiratory disease website. v2.2. 2022. https://www.pneumotox.com/drug/index/.

  122. Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Lilly. Retevmo (selpercatinib) package insert. Indianapolis, IN: Lilly; 2020.

    Google Scholar 

  124. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959–69.

    Article  CAS  PubMed  Google Scholar 

  125. Kim J, Bradford D, Larkins E, Pai-Scherf LH, Chatterjee S, Mishra-Kalyani PS, et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res. 2021;27(20):5452–6.

    Article  CAS  PubMed  Google Scholar 

  126. Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, et al. FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations. Clin Cancer Res. 2022;28(2):249–54.

    Article  CAS  PubMed  Google Scholar 

  127. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–57.

    Article  CAS  PubMed  Google Scholar 

  128. Hashiguchi MH, Sato T, Yamamoto H, Watanabe R, Kagyo J, Domoto H, et al. Successful tepotinib challenge after capmatinib-induced interstitial lung disease in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation: case report. JTO Clin Res Rep. 2022;3(2):100271.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA

    Kathleen A. McAvoy & Jennifer D. Possick

Authors
  1. Kathleen A. McAvoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer D. Possick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer D. Possick .

Editor information

Editors and Affiliations

  1. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA

    Christina R. MacRosty

  2. Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA

    M. Patricia Rivera

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

McAvoy, K.A., Possick, J.D. (2023). Pulmonary Complications of Lung Cancer Treatment. In: MacRosty, C.R., Rivera, M.P. (eds) Lung Cancer. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-031-38412-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38412-7_11

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-38411-0

  • Online ISBN: 978-3-031-38412-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation